PTC Therapeutics EBIT (Q1, 2019)-69.1 M

PTC Therapeutics Cash, 31-Mar-2019201.1 M

PTC Therapeutics EV2.4 B

USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 |
---|---|---|---|---|---|---|

## Revenue | 34.7m | 25.2m | 36.8m | 82.7m | 194.4m | 264.7m |

| (27%) | 46% | 125% | |||

## R&D expense | 54.9m | 121.8m | 117.6m | 117.5m | 172.0m | |

## General and administrative expense | 25.2m | 82.1m | 97.1m | 121.3m | 153.5m | |

## Operating expense total | 80.1m | 203.9m | 214.8m | 258.7m | 380.4m | |

## EBIT | (45.4m) | (99.4m) | (167.1m) | (132.1m) | (64.3m) | (115.7m) |

| (131%) | (394%) | (455%) | (160%) | (33%) | (44%) |

## Interest expense | 6.1m | 1.2m | 2.4m | 8.3m | 12.1m | 12.6m |

## Interest income | 1.2m | |||||

## Pre tax profit | (77.7m) | (128.1m) | ||||

## Income tax expense | (485.0k) | (569.0k) | (1.3m) | 29.0k | ||

## Net Income | (51.6m) | (93.8m) | (170.4m) | (142.1m) |

USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 |
---|---|---|---|---|---|---|

## Cash | 15.4m | 49.7m | 58.0m | 58.3m | 111.8m | 169.5m |

## Accounts Receivable | 11.1m | 24.9m | 40.4m | 67.9m | ||

## Inventories | 1.6m | 3.9m | 5.9m | 4.7m | 10.8m | 16.1m |

## Current Assets | 145.0m | 323.6m | 355.9m | 261.3m | 249.1m | 320.9m |

## PP&E | 6.7m | 9.0m | 8.4m | 12.7m | ||

## Goodwill | 82.3m | |||||

## Total Assets | 151.9m | 333.2m | 368.0m | 269.3m | 391.7m | 1.1b |

## Accounts Payable | 12.2m | 29.1m | 45.2m | 48.8m | 76.4m | 128.2m |

## Short-term debt | 48.6k | 49.0k | 11.7m | |||

## Current Liabilities | 13.1m | 32.5m | 45.4m | 49.6m | 82.0m | 166.8m |

## Long-term debt | 94.6m | 98.2m | 145.0m | 141.3m | ||

## Total Debt | 48.6k | 94.6m | 98.2m | 145.0m | 153.0m | |

## Total Liabilities | 15.4m | 142.0m | 149.8m | 235.2m | 768.5m | |

## Additional Paid-in Capital | 465.2m | 721.7m | 820.2m | 856.1m | 966.5m | 1.3b |

## Retained Earnings | (328.8m) | (422.6m) | (593.0m) | (735.1m) | (814.1m) | (938.9m) |

## Total Equity | 136.5m | 298.5m | 226.0m | 119.6m | 156.4m | 350.7m |

## Debt to Equity Ratio | 0.8 x | 0.9 x | ||||

## Debt to Assets Ratio | 0.4 x | 0.4 x | ||||

## Financial Leverage | 1.1 x | 1.1 x | 1.6 x | 2.3 x | 2.5 x | 3.2 x |

USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 |
---|---|---|---|---|---|---|

## Net Income | (51.6m) | (93.8m) | (170.4m) | (142.1m) | (79.0m) | (128.1m) |

## Depreciation and Amortization | 2.4m | 2.2m | 2.9m | 3.3m | 17.7m | 26.1m |

## Accounts Receivable | (6.9m) | (14.8m) | (12.2m) | (29.6m) | ||

## Inventories | (760.5k) | (2.3m) | (2.1m) | 1.2m | ||

## Accounts Payable | 5.2m | 16.9m | 17.0m | 4.3m | 24.0m | 43.9m |

## Cash From Operating Activities | (46.9m) | (57.3m) | (124.3m) | (103.6m) | (10.1m) | (27.6m) |

## Cash From Investing Activities | (127.8m) | (145.2m) | (20.8m) | 104.5m | 13.1m | (42.6m) |

## Long-term Borrowings | (5.0m) | (49.0k) | (49.0k) | |||

## Cash From Financing Activities | 187.4m | 237.1m | 154.1m | 968.0k | 44.2m | 131.6m |

## Interest Paid | 367.1k | 1.0k | 1.0k | 4.5m | 6.3m | 7.8m |

## Income Taxes Paid | 2.1k | 2.0k | 111.0k | 943.0k | 1.1m | 1.6m |

USD | Y, 2019 |
---|---|

## EV/EBIT | -34 x |

## EV/CFO | -55.5 x |

## Financial Leverage | 2.5 x |